The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSareum Share News (SAR)

Share Price Information for Sareum (SAR)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 24.25
Bid: 24.00
Ask: 24.50
Change: -1.00 (-3.96%)
Spread: 0.50 (2.083%)
Open: 25.25
High: 25.25
Low: 24.25
Prev. Close: 25.25
SAR Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK WINNERS & LOSERS SUMMARY: Mitchells & Butlers Down Amid Raise Plan

Thu, 07th Jan 2021 10:51

(Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Thursday.

----------

FTSE 100 - WINNERS

----------

J Sainsbury, up 3.8%. The grocer's like-for-like sales in the nine weeks to January 2 - so including the key festive period - were up 9.3% year-on-year. For the whole of its third-quarter, like-for-like sales, excluding fuel, climbed 8.6%. Including fuel, like-for-like sales were up a more modest 3.2%.

----------

FTSE 100 - LOSERS

----------

Experian, down 2.4%. The stock went ex-dividend, meaning new buyers no longer qualify for the latest payout.

----------

FTSE 250 - LOSERS

----------

Trainline, down 7.8%. Launched an offering of GBP150 million of senior unsecured convertible bonds due 2026. The train booking platform operator in UK said the net proceeds of the five-year bonds will "provide additional liquidity, protecting the business further in an extended Covid downturn".

----------

Mitchells & Butlers, down 7.0%. Reports sharp 67% sales fall for 14 weeks to January 2 and adds that it is mulling an equity raise.

----------

OTHER MAIN MARKET AND AIM - WINNERS

----------

Sareum Holdings, up 10%. The Cambridge-based drug developer said the US Patent Office approved its patent application for an invention associated with its SDC-1802 TYK2/JAK1 kinase inhibitor programme

----------

James Fisher & Sons, up 7.9%. The marine services provider saw improved trading in its fourth quarter, so now expects 2020 underlying profit to be at the upper end of its guided range.

----------

Synectics, up 4.9%. The Sheffield, England-based provider of security systems has successfully deployed the first phase of its operational management system for German railway operator S-Bahn in Berlin.

----------

OTHER MAIN MARKET AND AIM - LOSERS

----------

Ormonde Mining, down 29%. Adjourns annual general meeting scheduled for Thursday. The Spain-focused natural resources firm says this is so it can continue talks with its largest shareholder over motions six to eight, concerning its share capital and ability to make market purchases.

----------

Joules Group, down 6.1%. The retailer said sales in the seven months trading period to January 3 were better than expected, though in-store sales in the seven weeks to January 3 plunged 58%.

----------

By Eric Cunha; ericcunha@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
31 May 2018 12:17

Sareum Regains Worldwide Rights To Leukaemia Treatment

LONDON (Alliance News) - Sareum Holdings PLC said on Thursday that it has regained its worldwide rights to a potential treatment for leukaemia and other blood-related cancers.The drug said

Read more
15 Mar 2018 13:55

Sareum Partner Sierra Oncology To Present Positive SRA737 Results

LONDON (Alliance News) - Sareum Holdings PLC said Thursday its development partner Sierra Oncology's SRA737 results have been accepted for presentation at the annual of of

Read more
9 Jan 2017 16:39

Sareum Holdings receives milestone payment

(ShareCast News) - Sareum Holdings, an AIM listed specialist cancer drug discovery and development company, has announced the attainment of a $2m milestone payment as part of the Chk1 license agreement between its co-investment partner the CRT Pioneer Fund and Sierra Oncology, formerly known as ProN

Read more
9 Jan 2017 12:19

Sareum To Receive USD550,000 From Joint Licence Success Payment

Read more
24 Oct 2016 15:02

Sareum reports positive results from TYK2 programme

(ShareCast News) - Specialist cancer drug discovery and development business Sareum announced a successful conclusion from its feasibility study into the potential for its TYK2 programme lead molecules to treat T-Cell Acute Lymphoblastic Leukaemia (T-ALL) on Monday. The AIM-traded company said the i

Read more
24 Oct 2016 08:13

Sareum Welcomes Positive Feasibility Results For Leukemia Treatment

Read more
17 Oct 2016 14:16

Sareum Holdings granted patents in Japan and Singapore

(ShareCast News) - Specialist cancer drug discovery and development company Sareum announced on Monday that the Japan and Singapore Patent Offices have issued notifications that patents will be granted for inventions associated with its Aurora+FLT3 kinase inhibitor programme. The AIM-traded firm sai

Read more
27 Sep 2016 11:13

Sareum Holdings Co-Investment Partner Inks Licence Agreement

Read more
3 Aug 2016 14:56

Sareum programme receives patents in Hong Kong and China

(ShareCast News) - Specialist cancer drug discovery and development business Sareum announced on Wednesday that the Chinese Patent Office and the Hong Kong Patents Registry have issued notifications that patents will be granted for inventions associated with the company's Aurora+FLT3 Kinase Inhibito

Read more
23 May 2016 11:06

Sareum Holdings Says Phase I CCT245737 Trials To Open End Of May

Read more
23 May 2016 11:01

*Sareum Holdings Says Phase I CCT245737 Trials To Open End Of May

Read more
17 May 2016 08:03

Sareum Appoints Silence Therapeutics' Stephen Parker As Chairman

Read more
5 Apr 2016 12:33

Sareum cancer drug candidate gets MHRA trial approval

(ShareCast News) - Sareum Holdings was pressing ahead with one of its cancer drug programmes on Tuesday, having received approval from the Medicines and Healthcare products Regulatory Agency (MHRA) for the Clinical Trial Applications submitted for CHK1 inhibitor drug candidate CCT245737. The AIM-tra

Read more
5 Apr 2016 09:46

Sareum Holdings Gets Clinical Trial Approval For Cancer Drug Candidate

Read more
24 Mar 2016 12:03

Sareum Raises GBP1.1 Million For Drug Development Programmes (ALLISS)

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.